Table 2.

Effect of chronic administration of JNJ-40418677 on plaque area fraction and number of plaques in Tg2576 brain

		20 mg·kg−1·day−1 JNJ-40418677		60 mg·kg−1·day−1 JNJ-40418677		120 mg·kg−1·day−1 JNJ-40418677
Antibody	Measure of plaque burden	Mean reduction (%)	95% CI reduction (%)	Mean reduction (%)	95% CI reduction (%)	Mean reduction (%)	95% CI reduction (%)
4G8	% area	22	−143, 75	78	26, 93	96	86, 99
	# plaques	16	−131, 69	76	32, 92	95	86, 98
JRF/AbN/25	% area	−10	−208, 60	77	32, 92	92	78, 97
	# plaques	4	−131, 60	82	54, 93	95	87, 98
J&JPRDAß38/5	% area	30	−105, 76	55	−41, 86	82	47, 94
	# plaques	35	−46, 71	65	18, 85	88	72, 95
JRF/cAb40/28	% area	−21	−229, 56	74	25, 91	88	68, 96
	# plaques	0.5	−131, 57	74	38, 89	91	79, 96
JRF/cAb42/26	% area	6	−177, 68	84	51, 95	96	89, 99
	# plaques	10	−141, 66	80	44, 93	96	88, 98

Female Tg2576 mice were treated with 20, 60 or 120 mg·kg⁻¹·day⁻¹ JNJ-40418677 via a medicated diet from 6 to 13 months of age. Plaques were visualized with monoclonal antibodies 4G8 (against the Aβ mid-domain), JRF/AbN/25 (against full-length human Aβ) and J&JPRDAβ38/5, JRF/cAb40/28 and JRF/cAb42/26 against Aβ ending at amino acid 38, 40 and 42 respectively. Data are expressed as Dunnett adjusted geometric mean reduction (%) compared with vehicle-treated transgenic mice together with 95% CI (lower limit, upper limit). % area, % of total brain area occupied by plaques; # plaques, number of plaques mm² brain.